ArcticZymes Technologies — Board/Management Information 2018

Sep 20, 2018

Press release

Biotec Pharmacon changes management in the wound care area

(Tromsø 20 September 2018) Stuart Devine, who has been leading Biotec's efforts in introducing Woulgan® to the market for the last 3 years is leaving Biotec Pharmacon after a mutual agreement

Biotec Pharmacon has hired Mr. Finn Ketler to manage the wound care area going forward. Finn has a long and extensive background within medical devices and wound care. He spent 14 years in Coloplast with various roles of increasing responsibility, amongst others managing Coloplast's wound care division. Finn Ketler listed the Swedish medical device start-up Vigmed at Nasdaq First North in Stockholm as a CEO. Today Finn is acting as a Selection Committee member in BioInnovation Institutes (BII) Incubation programme – a position of trust Finn will continue to have. BII is a Novo Nordisk Foundation initiative.

Finn Ketler is a Danish national and has a M.Sc. from Aarhus Business School.

"I would like to take this opportunity to thank Stuart for his 3 years of hard work in developing the Woulgan business and also extend a warm welcome to Finn on the team", says CEO Christian Jørgensen.

The transition of roles will take place over the next quarter.

For more information, please contact: CEO Christian Jørgensen, tel +47 47 79 24 57

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and ArcticZymes AS. ArcticZymes develops, produces and markets enzymes of marine origin used in molecular DNA technologies and diagnostics, representing growth markets where rapid technological developments are creating a strong demand for new and improved enzymes.